{"id":"crofelemer-powder-for-oral-solution","safety":{"commonSideEffects":[{"rate":"10%","effect":"Diarrhea"},{"rate":"8%","effect":"Nausea"},{"rate":"6%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2108184","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Crofelemer works by inhibiting the SGLT2 protein in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine.","oneSentence":"Crofelemer is a plant-derived inhibitor of the sodium glucose cotransporter 2 (SGLT2)","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:38.521Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diarrhea-predominant irritable bowel syndrome (IBS-D)"}]},"trialDetails":[{"nctId":"NCT06326645","phase":"EARLY_PHASE1","title":"Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome","status":"RECRUITING","sponsor":"Lindsey Russell, MD","startDate":"2025-03-03","conditions":"Short Bowel Syndrome","enrollment":6},{"nctId":"NCT06721871","phase":"PHASE2","title":"Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)","status":"RECRUITING","sponsor":"Napo Pharmaceuticals, Inc.","startDate":"2025-05-01","conditions":"Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases","enrollment":12},{"nctId":"NCT06904872","phase":"PHASE2","title":"Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)","status":"RECRUITING","sponsor":"Napo Therapeutics, S.p.A.","startDate":"2025-05-29","conditions":"Short Bowel Syndrome, Malabsorption Syndromes, Short Gut Syndrome","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Crofelemer Powder for Oral Solution","genericName":"Crofelemer Powder for Oral Solution","companyName":"Napo Therapeutics, S.p.A.","companyId":"napo-therapeutics-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Crofelemer is a plant-derived inhibitor of the sodium glucose cotransporter 2 (SGLT2) Used for Diarrhea-predominant irritable bowel syndrome (IBS-D).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}